8 / 9
E u r o p e a n C o n g r e s s o n
Vaccines & Vaccination
and Gynecologic Oncology
Journal of Clinical Immunology and Allergy
ISSN: 2471-304X
O c t o b e r 2 6 - 2 7 , 2 0 1 8
B u d a p e s t , H u n g a r y
Vaccines & Vaccination and Gynecologic Oncology 2018
Page 35
Biography
AlexanderSuvorov,MD,hascompletedhisPhDinBiochemistryin
the Institute of Experimental Medicine, Russia and Postdoctoral
studies from Minnesota and Oklahoma Universities. He is
the Head of the Department of Molecular Microbiology in the
Institute of Experimental Medicine, Saint-Petersburg Russia;
Head and Professor of the Faculty of Fundamental Medicine
in Saint-Petersburg State University. He has published more
than 100 papers in reputed journals and has been serving as
an Editorial Board Member of several Russian and International
Journals. Recently, he became a Corresponding Member of
Russian Academy of Science.
Alexander_suvorov1@hotmail.comNovel vaccines against
Streptococcus
agalactiae
infection
Alexander Suvorov
1,2
, Galina Leontieva
1
,
Tatiana Kramskaya
1
, Iliya Dukhovlinov
1
,
Tatiana Gupalova
1
, Kornelia Grabovskaya
1
and Viktoria Filimonova
1
1
Institute of Experimental Medicine, Russia
2
Saint Petersburg State University, Russia
Alexander Suvorov et al., Journal of Clinical Immunology and Allergy, Volume: 4
DOI: 10.21767/2471-304X-C2-004
Introduction:
Streptococcus agalactiae
(group B streptococcus–GBS) is a severe
human pathogen causing diseases in newborns and elderlies. This makes GBS
infection an importantmedical and social problemrequiting vaccine prophylactics.
Presently, there are couple vaccine candidates in testing. However, there are no
GBS vaccines in the market. Present work describes the results of several variants
of GBS vaccines based on recombinant surface expressed proteins.
Materials & Methods:
Recombinant GBS proteins were obtained after cloning
of the gene fragments encoding for the immunogenic epitopes of the surface
expressed proteins and expressing them in the
E.coli
. Recombinant chimeric
vaccines were generated after chemical synthesis of DNA molecules encoding
for several immunogenic epitopes belonging to different proteins. Artificial
DNA was cloned in the
E.coli
expression vectors with the following isolation of
recombinant chimeric proteins. Life vaccines were developed after incorporation
of the streptococcal DNA into the probiotic strains chromosome. Immunogenicity
and protectiveness were tested on various mice models. Antibody levels were
tested by ELISA.
Results & Conclusion:
We have developed several streptococcal vaccine
candidates based on different approach–making the mixture of recombinant
proteins or making recombinant chimeric vaccines consisting from several
immunogenic surface proteins epitopes artificially assembled in one protein
molecule. These GBS vaccines against S. agalactiae had been tested on several
experimental models which proved their immunogenicity and are protective.
This approach had been expanded for making new life vaccines for mucosal
immunization with expression of streptococcal vaccine antigens by the probiotic
bacteria as delivery vehicles. These probiotic vaccines had been also shown to
be immunogenic and protective. The future of practical implication of novel
streptococcal vaccine candidates is discussed.
Euro Vaccines 2018